Net profit of Mankind Pharma rose 65.09% to Rs 471.24 crore in the quarter ended March 2024 as against Rs 285.44 crore during the previous quarter ended March 2023. Sales rose 18.92% to Rs 2441.10 crore in the quarter ended March 2024 as against Rs 2052.67 crore during the previous quarter ended March 2023.For the full year,net profit rose 49.23% to Rs 1912.90 crore in the year ended March 2024 as against Rs 1281.86 crore during the previous year ended March 2023. Sales rose 18.12% to Rs 10334.77 crore in the year ended March 2024 as against Rs 8749.43 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales2441.102052.67 19 10334.778749.43 18 OPM %24.2120.30 -24.5321.72 - PBDT676.26461.81 46 2797.611997.16 40 PBT571.58377.29 51 2399.361671.24 44 NP471.24285.44 65 1912.901281.86 49 Powered by Capital Market - Live News

Mankind Pharma has allotted 46,698 equity shares under ESOP on 10 May 2024. With this allotment, the paid up equity share capital has increased to 40,06,35,138 equity shares having face value of Re. 1/- each. Powered by Capital Market - Live News

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 15 May 2024Powered by Capital Market - Live News

The Board of Mankind Pharma at its meeting held on 02 April 2024 has approved slump sale of Over the Counter business of the company to wholly owned subsidiary company proposed to be incorporated with the name of Manking Consumer Products or any other name as approved by Ministry of Corporate Affairs. The transaction will be effective on or before 01 October 2024 or such other date as may be mutually agreed between the parties, subject to customary closing conditions. The Company will continue to have business operations with the proposed incorporated entity on arm`s length basis. The Board approved incorporation of a wholly owned subsidiary by the name Mankind Consumer Products or any other name approved by Registrar of Companies, Ministry of Corporate Affairs. Powered by Capital Market - Live News

Net profit of Mankind Pharma rose 59.69% to Rs 453.76 crore in the quarter ended December 2023 as against Rs 284.15 crore during the previous quarter ended December 2022. Sales rose 24.68% to Rs 2606.96 crore in the quarter ended December 2023 as against Rs 2090.93 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales2606.962090.93 25 OPM %23.2620.90 - PBDT672.06463.78 45 PBT562.33378.99 48 NP453.76284.15 60 Powered by Capital Market - Live News